(NASDAQ: CRBU) Caribou Biosciences's forecast annual revenue growth rate of 42.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Caribou Biosciences's revenue in 2026 is $8,806,000.On average, 10 Wall Street analysts forecast CRBU's revenue for 2026 to be $1,124,806,901, with the lowest CRBU revenue forecast at $971,969,635, and the highest CRBU revenue forecast at $1,249,675,245. On average, 9 Wall Street analysts forecast CRBU's revenue for 2027 to be $1,247,790,814, with the lowest CRBU revenue forecast at $1,106,359,314, and the highest CRBU revenue forecast at $1,562,094,056.
In 2028, CRBU is forecast to generate $2,770,510,182 in revenue, with the lowest revenue forecast at $1,117,467,539 and the highest revenue forecast at $10,413,960,375.